Computer Vision News - September 2020

Paige 11 written the very first paper in this space back in 2008. He built the lab at MSK that started developing these technologies. Over the last couple of years, we have assembled a fantastic team from both healthcare and non- healthcare industry backgrounds , who have a collection of strengths from design to regulatory to commercialization to machine learning. We even have NASA alumni who were doing machine learning on satellite imagery. We are 50 people now and have achieved a huge amount. That is a testament to the whole team.” The technology created by Paige is classed as Software as aMedical Device, so before it can be sold or marketed, it needs governmental clearance. This means the time to market can vary from country to country. For Paige Prostate , its prostate cancer detection technology, the time to receive its CE mark was around four months. In the US, the situation is quite different. There are currently no computational pathology solutions cleared in the US, but Paige hopes to change this . The global pandemic has caused some delays, but in July it got FDA clearance for its Viewer , which is how it delivers AI solutions in Europe . This was not planned for this year, but a performant web-based viewer for primary diagnosis can help pathologists to work remotely, so Paige prioritized its roadmap and submitted it for clearance back in April when the world was locking down. Now, it has the potential to distribute its computational pathology solutions on its own viewer in a more workflow- friendly way. “We are hoping to have our first product cleared next year on the computational pathology side,” Carla says keenly. “I